Preclinical review of cerivastatin sodium - A step forward in HMG-CoA reductase inhibition

Atherosclerosis

Volumn 139, Issue SUPPL. 1, 1998, Pages 7-

  Bischoff, H ^a   Angerbauer, R ^a   Boberg, M ^a   Petzinna, D ^a   Schmidt, D ^a   Steinke, W ^a   Thomas, G ^a  

^a BAYER AG   (Germany)

Author keywords

Cerivastatin sodium metabolism; Cholesterol; HMG CoA reductase inhibitors

Indexed keywords

ACETIC ACID; CARBON 14; CERIVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER; COLESTYRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AREA UNDER THE CURVE; CHOLESTEROL SYNTHESIS; CONFERENCE PAPER; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; LIVER CLEARANCE; LIVER MICROSOME; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RABBIT; RAT;

EID: 0031669341     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0021-9150(98)00188-9     Document Type: Conference Paper

References (22)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 1989;320:915-24.
3. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. New Engl J Med 1995;332:512-21.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333:1301-7.
5. The MARS Research Group, Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, et al. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). Ann Intern Med 1993;119:969-76.
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study Group (4S). Lancet 1994;334:1383-1389.
7. Lipid Research Program. The lipid research clinics coronary prevention trial results I. Reduction in incidence of coronary heart disease, II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 1984;251:351-374.
8. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1994;33:1569-82.
9. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffmann C, Rothrock J, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutarylcoenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980;77:3957-61.
10. Tsujita Y, Kuroda M, Shimada Y, Tanzawa M, Kaneko I, Tanaka M, et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibitor of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 1986;877:50-60.
11. Kovanen PT, Bilheimer DW, Goldstein JL, Jaramillo JJ, Brown MS. Regulatory role of hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA 1981;78:1194-8.
12. Chao Y, Chen JS, Hunt VM, Kuron GW, Karkas JD, Liou R, et al. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Eur J Clin Pharmacol 1991;40:S11-4.
13. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharm Res 1995;31:9-27.
14. Krause BR, Newton RS. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 1995;117:237-44.
15. Bischoff H, Angerbauer R, Bender J, Bischoff E, Faggiotto A, Petzinna D, et al. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 1997;135:119-30.
16. The Cerivastatin Study Group, Stein E, Sprecher D, Allenby KS, Tosiello RL, Whalen E, et al. Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 1997;2:7-16.
17. Bischoff H, Angerbauer R, Boberg M, Schmidt D. Cerivastatin: high enzyme affinity and active metabolises contribute to its high pharmacological activity. Atheroscierosis 1997;130:25.
18. Steinke W, Yamashita S, Tabei M, Ahr HJ, Beckermann B, Domdey-Bette A, et al. Cerivastatin, a new inhibitor of HMG-CoA reductase: pharmacokinetics in rats and dogs. Jpn Pharmacol Ther 1996;24:S1217-37.
19. Muck W, Ritter W, Ochmann U, Unger S, Ahr G, Wingender W, et al. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Therap 1997;35(6):255-60.
20. Mazzu A, Lettieri J, Kaiser L, Frey R, Heller AH. Ascending multiple dose safety, tolerability and pharmacokinetics of rivastatin in humans. Clin Pharmacol Ther 1993;53:230, Abstract no. PIII-95.
21. Muck W, Kawano K, Ahr G. Interethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol 1998;45:583-90.
22. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, et al. Metabolism of cerivastatin by human liver microsomes in vitro. Drug Metab Dispos 1997;25:321-31.